Hypermagnesaemia is an unusual complication of allogeneic haemopoietic stem cell transplantation (HSCT). In one series of 311 patients undergoing allogeneic HSCT, severe hypermagnesaemia was reported in nine cases.
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Hypermagnesaemia is a well-recognised complication of laxative use, usually occurring in patients with renal dysfunction or small bowel hypomotility disorders. Magnesium in excess acts as a competitive calcium channel blocker, producing the clinical features of hypotension, autonomic dysfunction, cardiac conduction defects and neuromuscular junction blockade. To our knowledge, this complication has not been reported in the setting of acute gastrointestinal graft-versus-host disease (GVHD).
We report the case of a 43-year-old man, who developed life-threatening hypermagnesaemia associated with laxative use, following HLA-matched sibling non-myeloablative peripheral blood stem cell transplantation for M1 acute myeloid leukaemia (AML) in first complete remission (CR1). There was no significant past medical history. Remission induction was achieved using the ICE regimen (idarubicin 9 mg/m 2 daily Â 3, cytarabine 3 gm/m 2 twice daily Â 4, etoposide 75 mg/m 2 daily Â 7) but was complicated by multiorgan failure. Following two cycles of consolidation chemotherapy, he was enrolled in a trial of non-myeloablative HSCT for AML in CR1. He was conditioned with cyclophosphamide and fludarabine, and received 8.67 Â 10 6 /kg CD34 þ cells harvested from his male sibling donor. Graft-versus-host disease prophylaxis consisted of cyclosporine A 3 mg/kg/day and methotrexate. On day þ 23 after HSCT, a maculopapular trunk rash consistent with stage II acute skin GVHD was noted. It resolved with oral prednisolone 100 mg daily. On day þ 28 after HSCT he developed diarrhoea. Stool microbiology was negative. From day þ 32, because of progressively worsening diarrhoea, he received intravenous methylprednisolone 500 mg daily for 3 days, followed by 180 mg daily. By day þ 34, the serum creatinine rose to 221 mmol/l from a normal baseline. On day þ 35 he received 2 Picolax (10 mg sodium picosulphate and 20 g magnesium carbonate), and 1 l of Colonlytely, a polyethylene glycol-based electrolyte solution, in preparation for colonoscopy. While ingesting these products, he developed a moderate hyporeflexic tetraparesis, accompanied by facial diplegia, fatiguable ptosis, a complex ophthalmoplegia, bulbar palsy, and tongue weakness. His serum magnesium at this time was 4.94 mmol/l, from 1.21 mmol/l that morning. Serum calcium and potassium were normal. On the same day, he developed oliguria secondary to intravascular hypovolaemia. His cyclosporine concentration was 433 mg/l and this drug was withheld. Features consistent with an ileus were noted, including cessation of previously profuse bowel movements. Some increase in strength was noted with calcium gluconate administration, and a saline diuresis was attempted. The following day, creatinine continued to rise and magnesium remained elevated at a concentration of 4.4 mmol/l. Haemodialysis was commenced with a postdialysis magnesium of 1.97 mmol/l. Towards the end of the first dialysis, profuse bowel movements recommenced, and strength returned to pre-morbid concentrations. Nerve conduction studies were performed at this stage, showing an inconsistent increment at 2 Hz, and saddle-shaped increment at 20 and 30 Hz. There was no post-exercise facilitation. Dialysis was repeated the following day. On day þ 37, mycophenolate mofetil 500 mg intravenously twice daily was empirically commenced for ongoing diarrhoea. The diagnosis of GVHD was supported by biopsy findings from sigmoidoscopy. Severe diarrhoea persisted, despite subsequent reintroduction of cyclosporine, and daclizumab, etanercept, antithymocyte globulin and oral budesonide. Active therapy was withdrawn due to ongoing bloody diarrhoea, and the patient succumbed to GVHD.
Magnesium absorption occurs largely from the small intestine, with absorption in normal subjects beginning 1 h after ingestion and peak serum concentrations occurring 4-6 h after ingestion. 2 Our patient showed the typical neurological features of hypermagnesaemia. Magnesium acts as a competitive calcium channel blocker, inhibiting fusion of acetylcholine vesicles with the pre-synaptic membrane, causing failure of neuromuscular transmission. Classical electrophysiologic studies are identical to studies from patients with the Lambert-Eaton myasthenic syndrome (an immune disorder of pre-synaptic calcium channels), showing decrement at low frequencies, increment at high frequencies and post-exercise facilitation.
in ionic concentrations. Our patient responded well to intravenous calcium.
Our case was remarkable for the speed and extent of the hypermagnesaemia from a single oral dose of cathartic preparation. We hypothesise that this occurred due to greater permeability of the small intestinal mucosa in its inflamed state. Hypermagnesaemia secondary to magnesium-containing cathartics has been reported only once previously in an allogeneic HSCT recipient; no mention was made of gastrointestinal GVHD. 4 Picolax contains a high concentration of magnesium. Its use has been supported by several small, randomised, controlled trials as bowel preparation for sigmoidoscopy or abdominal computerised tomography. None of these reported electrolyte imbalances in their subjects. 5, 6 Although Picolax may cause hypermagnesaemia, particularly in the setting of renal failure, the acuteness and severity of hypermagnesaemia in this case suggest a pathophysiologic role of gastrointestinal GVHD. High intraluminal magnesium concentration and increased intestinal permeability in its inflamed state, we believe combined to result in a rapid rise in serum magnesium concentration. Our patient's experience suggests that magnesium-containing laxatives should be avoided in patients with severe gastrointestinal GVHD. To our knowledge, there are no data on the yield of sigmoidoscopy without rigorous bowel preparation in this group of patients. Such data should be the subject of further investigation. 
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